PRODUCT INFORMATION



Amlodipine (besylate)

Item No. 14886

CAS Registry No.:	111470-99-6	
Formal Name:	2-[(2-aminoethoxy)methyl]-4-(2-	<u>^</u>
	chlorophenyl)-1,4-dihydro-6-methyl-	
	3,5-pyridinedicarboxylic acid, 3-ethyl	││
	5-methyl ester, monobenzenesulfonate	
MF:	$C_{20}H_{25}CIN_2O_5 \bullet C_6H_6O_3S$	
FW:	567.1	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 237 nm	N NH2
Supplied as:	A solid	L L
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

Amlodipine (besylate) is supplied as a solid. A stock solution may be made by dissolving the amlodipine (besylate) in the solvent of choice, which should be purged with an inert gas. Amlodipine (besylate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of amlodipine (besylate) in ethanol is approximately 1 mg/ml and approximately 5 mg/ml in DMSO and DMF.

Description

Amlodipine is a dihydropyridine L-type calcium channel blocker that selectively inhibits calcium influx in cardiac and vascular smooth muscle.¹ Acting as a vasodilator, amlodipine reduces blood pressure by relaxing the smooth muscle in the arterial wall, decreasing total peripheral resistance. It inhibits calcium-induced contractions in depolarized rat aorta with an IC₅₀ value of 1.9 nM, displaying a slow rate of association and dissociation in isolated vascular and cardiac tissues. Amlodipine also demonstrates actions independent of L-type calcium channel blockade by regulating membrane fluidity and cholesterol deposition, stimulating nitric oxide production, acting as an antioxidant, and regulating matrix deposition in vitro and in vivo.² Formulations containing amlodipine have been used in the treatment of hypertension.

References

- 1. Burges, R.A., Gardiner, D.G., Gwilt, M., et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: Evidence for voltage modulation of vascular dihydropyridine receptors. J. Cardiovasc. Pharmacol. 9(1), 110-119 (1987).
- 2. Mason, R.P., Marche, P., and Hintze, T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: Ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23(12), 2155-2163 (2003).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM